Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity.

Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Abstract Text:

    weizhu qianWeizhu Qian,ling wangLing Wang,bohua liBohua Li,hao wangHao Wang,sheng houSheng Hou,xueyu hongXueyu Hong,dapeng zhangDapeng Zhang,yajun guoYajun Guo,weizhu qianWeizhu Qian,ling wangLing Wang,bohua liBohua Li,hao wangHao Wang,sheng houSheng Hou,xueyu hongXueyu Hong,dapeng zhangDapeng Zhang,yajun guoYajun Guo,

    Despite the widespread clinical use of CD34 antibodies for the purification of human hematopoietic stem/progenitor cells, all the current anti-human CD34 monoclonal antibodies (mAbs) are murine, which have the potential to elicit human antimouse antibody (HAMA) immune response. In the present study, we developed three new mouse anti-human CD34 mAbs which, respectively, belonged to class I, class II and class III CD34 epitope antibodies. In an attempt to reduce the immunogenicity of these three murine mAbs, their chimeric antibodies, which consisted of mouse antibody variable regions fused genetically to human antibody constant regions, were constructed and characterized. The anti-CD34 chimeric antibodies were shown to possess affinity and specificity similar to that of their respective parental murine antibodies. Due to the potentially better safety profiles, these chimeric antibodies might become alternatives to mouse anti-CD34 antibodies routinely used for clinical application.

    Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Publishing Authors By Initials

    w qianW Qian,l wangL Wang,b liB Li,h wangH Wang,s houS Hou,x hongX Hong,d zhangD Zhang,y guoY Guo,w qianW Qian,l wangL Wang,b liB Li,h wangH Wang,s houS Hou,x hongX Hong,d zhangD Zhang,y guoY Guo,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Biochemical and biophysical research communication

    VOLUME: 367

    Page Numbers: 497-502

    Journal Abbreviation: Biochem. Biophys. Res. Commun.

    ISSN: 1090-2104

    DAY: 9

    MONTH: 01

    YEAR: 2008

    Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 372516

    Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity.

    AFFILIATION: International Joint Cancer Institute, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People's Republic of China.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Biochem Biophys Res Commun

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News